Lisa Faia, MD
Retina Specialist · Royal Oak, MINPI 1407832884
Payments from drug & device makers
Across 599 payments — averaging $1097.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$103K
- Astellas Pharma US Inc$100K
- Gilead$99K
- Genentech USA, Inc.$88K
- AbbVie$74K
- Regeneron Healthcare Solutions, Inc.$54K
- plus $139K from 23 others
Across 1 payment — averaging $9600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$10K
What the payments were for
- Consulting fees$57,73311%
- Speaking & faculty fees$407,83678%
- Travel & lodging$32,2736%
- Food & beverage$22,4444%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 52 | $103,261 |
| Astellas Pharma US Inc | 69 | $100,453 |
| Gilead | 24 | $98,814 |
| Genentech USA, Inc. | 83 | $87,974 |
| AbbVie(2 entities) | 76 | $73,523 |
| Regeneron Healthcare Solutions, Inc. | 65 | $53,899 |
| Eyepoint US, Inc. | 42 | $45,244 |
| ANI Pharmaceuticals, Inc. | 43 | $30,772 |
| Janssen Research & Development, LLC | 6 | $13,395 |
| Genentech, Inc. | 6 | $12,716 |
| Janssen Global Services, LLC | 6 | $11,395 |
| Ocular Therapeutix, Inc. | 10 | $9,471 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $6,178 |
| Harrow Eye, LLC | 3 | $5,660 |
| Bausch & Lomb Americas Inc. | 27 | $1,345 |
| Apellis Pharmaceuticals, Inc. | 19 | $591 |
| Coherus Oncology, Inc. | 7 | $448 |
| Mallinckrodt Enterprises LLC | 16 | $432 |
| Sandoz | 4 | $358 |
| Oculus Surgical Inc. | 3 | $259 |
| Mallinckrodt Hospital Products Inc. | 12 | $209 |
| Regeneron | 1 | $125 |
| Alcon | 3 | $119 |
| Novartis | 6 | $116 |
| Astellas Pharma Global Development | 1 | $107 |
| Thrombogenics, Inc. | 1 | $77 |
| Biogen | 3 | $72 |
| Samsara Vision | 1 | $59 |
| Astellas US LLC | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$657,116 in reported general payments places this provider in the 95th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 273 | $17,703 |
| NevanacNepafenac | 28 | $8,875 |
| Ketorolac Tromethamine | 204 | $4,704 |
| ValacyclovirValacyclovir Hcl | 15 | $1,744 |
| Difluprednate | 15 | $1,568 |
| Ofloxacin | 22 | $503 |
| ErythromycinErythromycin Base | 31 | $445 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $434 |
| Prednisone | 35 | $419 |
| Dorzolamide Hcl | 13 | $327 |
| Brimonidine Tartrate | 11 | $110 |
| Latanoprost | 11 | $108 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Royal Oak
- Jeremy WolfeRoyal Oak$3.6M
- Tarek HassanRoyal Oak$801K
- Antonio CaponeRoyal Oak$179K
- Sandeep RandhawaRoyal Oak$98K
- Kimberly DrenserRoyal Oak$87K
- Michael TreseRoyal Oak$69K
- Adam WeinerRoyal Oak$31K
- Ramon LeeRoyal Oak$19K
- Jong ParkRoyal Oak$12K
- Tianyu LiuRoyal Oak$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.